# DAPAGLIFLOZIN AND METFORMIN
> **ANDA220642** · Abbreviated New Drug Application (Generic) · Sponsor: SCIEGEN PHARMACEUTICALS · Approved 2026-07-16
## Drug
- **FDA Application Number:** ANDA220642
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** DAPAGLIFLOZIN AND METFORMIN
- **Generic name:** Dapagliflozin, Metformin
- **Active ingredients:** DAPAGLIFLOZIN, METFORMIN
- **Dosage form:** TABLET, EXTENDED RELEASE
- **Route:** —
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** SCIEGEN PHARMACEUTICALS
- **First approval:** 2026-07-16
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220642)
---
*MORVS · CC0 1.0*